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Abstract The ubiquitin–proteasome system (UPS)
degrades intracellular proteins into peptide fragments that
can be presented by major histocompatibility complex
(MHC) class I molecules. While the UPS is functional in all
mammalian cells, its subunit composition differs depending
on cell type and stimuli received. Thus, cells of the hema-
topoietic lineage and cells exposed to (pro)inﬂammatory
cytokines express three proteasome immunosubunits, which
form the catalytic centers of immunoproteasomes, and the
proteasome activator PA28. Cortical thymic epithelial cells
express a thymus-speciﬁc proteasome subunit that induces
the assembly of thymoproteasomes. We here review new
developments regarding the role of these different protea-
some components in MHC class I antigen processing, T cell
repertoire selection and CD8 T cell responses. We further
discuss recently discovered functions of proteasomes in
peptide splicing, lymphocyte survival and the regulation of
cytokine production and inﬂammatory responses.
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The ubiquitin–proteasome system
Cell-surface-expressed major histocompatibility complex
(MHC) class I molecules present antigenic peptides to the
outside world so that they can be speciﬁcally recognized by
cytotoxic T lymphocytes (CTLs) [1]. These specialized T
cells can detect other cells that endogenously express for-
eign or aberrant (i.e. mutated) protein molecules and
subsequently remove these unwanted cells from the body.
Recognition fully depends on the binding of antigenic
peptides into the groove of MHC class I molecules [2, 3].
The generation of these peptides requires the degradation
of proteins by the 26S proteasome into peptide fragments
of a size appropriate for transport by the transporter asso-
ciated with antigen presentations (TAPs) into the
endoplasmic reticulum (ER) or for docking to the peptide
binding groove of the MHC class I molecule [4–7].
The 26S proteasome is the central proteolytic enzyme
complex of the ubiquitin–proteasome system (UPS) and
responsible for the degradation of poly-ubiquitylated pro-
teins formed by a cascade of E1, E2 and E3 enzymes,
which activate, conjugate and transfer multiple ubiquitin
(ub) moieties to protein substrates to be degraded [8]. The
multiple subunit 20S proteasome is the catalytic core of
the 26S proteasome, which is built by the association of the
20S core complex with two 19S regulator complexes that
are responsible for the activation of the 20S core as well as
for the binding and unfolding of ubiquitylated substrates
[19S–20S–19S] [9, 10].
The 20S proteasome is composed of 14 non-identical
subunits building four stacked rings of seven subunits each.
Seven different but related a-subunits (a1–a7) form the two
outer a-rings, whereas the two inner rings contain seven
different b-subunits (b1–b7) [11, 12]. With its N-terminal
threonine residues as the single active site of the b-subunits
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123b1, b2 and b5, the 20S proteasome is a N-terminal
nucleophilic hydrolase responsible for the generation of the
vast majority of virus or tumor-derived peptides presented
by MHC class I molecules at the cell surface.
The three active site subunits differ in their ability to
hydrolyze short ﬂuorogenic peptide substrates. Accord-
ingly, the activities are referred to as chymotrypsin-like
(b5), trypsin-like (b2), or caspase-like (b1) [11]. Not
neglecting certain preferences, cleavage site usage by the
proteasome is promiscuous in that almost every amino acid
residue can serve as a cleavage site, giving the enzyme
complexa high degree of ﬂexibility with regard to quality of
the products that are generated [7, 13, 14]. The reasons why
proteasomes emerged as the main protease thought to be
involved in the generation of MHC class I epitope are
several-fold. First of all, proteasomes preferentially cleave
at the carboxy-terminus after hydrophobic or basic residues
thereby preferentially generating the C-terminal anchor
residue of MHC class I epitopes. Secondly, proteasomes
generate peptides of 8–10 amino acids in length and thus of
a size suited for binding to MHC class I molecules [15].
Furthermore, inhibition of proteasome activity using spe-
ciﬁc inhibitors abolished MHC class I antigen presentation
almost completely [4, 16]. The most profound inﬂuence on
the notion that proteasomes are involved in antigen
processing resulted, however, from the ﬁnding that, upon
IFN-c induction, speciﬁc catalytically active b-subunits, i.e.
b1i/LMP2, b2i/MECL1 and b5i/LMP7, are incorporated
into nascent proteasomes to form 20S proteasome com-
plexes with an alternative subunit composition [17]. Two of
these subunits (b1i/LMP2, b5i/LMP7) are encoded within
the MHC class II region [18–21], which led to the terms
immunosubunits (i-subunits) and immunoproteasome
(i-proteasome) [22] implying that these enzyme complexes
are responsible for antigen presentation. Because of this
change in active site subunits, immunoproteasomes have an
altered cleavage site preference as well as a different
cleavage rate [23–26]. The previously identiﬁed proteasome
maturation protein is also up-regulated by IFN- and accel-
erates immunoproteasome formation through functional
interaction with the b5i subunit [27].
Thus, two types of proteasomes exist, i.e. standard
proteasomes that are constitutively expressed in all cells of
an organism, and immunoproteasomes that are constitu-
tively expressed in immune relevant cells and are formed
upon exposure of cells to IFN-c or particular proinﬂam-
matory cytokines, as discussed below.
The emerging picture appeared to be complete when the
proteasome activator subunits PA28a and PA28b [28, 29],
which bind to the outer a-rings of the 20S proteasome
thereby forming so-called hybrid-proteasomes [19S–20S–
PA28] [30, 31], were also found to be induced by IFN-c
[32]. Expression of PA28, however, is not restricted to
IFN-c induction, but is found in almost all tissues analyzed.
Biochemical studies revealed that PA28 does not activate
the proteasome by directly affecting the hydrolyzing
activities of the different active sites buried in the catalytic
cavity [33, 34]. In contrast, structural and biochemical
evidence suggests that, by binding to the outer a-rings of
the 20S proteasome, PA28 causes the N-terminal tails of
the a-subunits to ﬂip upwards, thereby facilitating substrate
entry and product exit through the otherwise closed central
‘gate’ of the 20S proteasome [35, 36]. On the basis of these
observations, it was suggested that such an open confor-
mation might support the release of longer N-terminally-
extended peptides, which were assumed to be adapted to
the requirements of antigen presentation. However, binding
of the 19S regulator also results in the complete opening of
the gates [37]. Thus, it is unlikely that observed biological
effects of PA28 function (see further down) are primarily
the result of a gated 20S proteasome conﬁguration. Indeed,
PA28-deﬁcient mice are viable suggesting a more spe-
cialized function for this protein [38].
Proteasomal antigen processing and contribution
of immunosubunits
The early ﬁnding that in vitro experiments, using puriﬁed
20S proteasomes (standard and immuno), in combination
with synthetic peptide substrates encompassing the epitopes
and the natural ﬂanking sequences, reproduced the obser-
vations made in intact cellular systems with surprisingly
high ﬁdelity [24, 39], led to a detailed analysis of a large
number of different antigenic peptides of viral, bacterial and
humanorigin.Animportantoutcomeoftheseexperimentsis
that both standard and immunoproteasomes are able to
generateMHCclass I epitopes.Nevertheless,there canexist
dramatic differences between the two subtypes with respect
to the efﬁciency at which a given epitope can be generated.
Forexample,experimentsinwhichHeLacellswereinfected
with vaccinia virus expressing the hepatitis B virus (HBV)
coreantigenrevealedanefﬁcient liberationandpresentation
of the HBVcAg141–151 epitope [40]. However, presentation
of this epitope essentially required the stimulation of HeLa
cells with IFN-c and the formation of immunoproteasomes.
Thus, no measurable peptide-speciﬁc CTL response was
triggered in the presence of standard proteasomes only.
Similarly, processing of a Mage-3-derived epitope essen-
tially requires the presence of immunoproteasomes [41]. In
contrast, the generation of a melanocyte Melan-A-derived
tumor epitope was reported to be signiﬁcantly impaired in
the presence of immunoproteasomes [42].
Since the vast majority of peptides generated by the
proteasome will be readily degraded by aminopeptidases
[43, 44], the question arises how the sufﬁcient and
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and whether immunoproteasomes and PA28 are involved
in this process. Two alternative scenarios may apply.
Immunoproteasomes/PA28 generate antigenic peptides
using alternative cleavage sites. In this case, a qualitatively
completely different set of peptides ought to be generated,
which is possibly more adapted to TAP-dependent trans-
port and the requirements of MHC class I binding than the
one produced by standard proteasomes. Or, immunopro-
teasomes/PA28 generate a similar set of peptides as
standard proteasomes, but by increased amounts and more
efﬁciently to overcome the high peptide destruction rate
within the cell to satisfy the needs of increased peptide
supply. Approaching these questions from either a bio-
chemical or more immunological perspective, however,
will strongly inﬂuence the answers.
Experiments using a mouse embryonal cell line with
TET-regulated expression of the immunosubunits and
peptide-speciﬁc CTL assays as a ‘read-out’ system indi-
cated that standard proteasomes barely generated the
adenovirus E1B-derived epitope while the same epitope
was efﬁciently generated by 20S immunoproteasomes and
that the amount of in vitro-generated E1B-derived closely
correlated with the effect of immunoproteasomes in in vivo
experiments [45]. Accepting CTL assays as the most sen-
sitive immunological read-out to assess cellular proteasome
function, one has to conclude that immunoproteasomes
strongly determine the quality of epitope generation and as
such also the immune recognition of a cell or tissue [46].
However, as determined by mass spectrometric (MS)
analysis, standard proteasomes also generate ‘‘immuno-
proteasome-dependent’’ epitopes such as the adenovirus
E1B epitope, albeit with a dramatically reduced efﬁciency.
This ﬁnding was conﬁrmed in later studies of E1B epitope
presentation by GM-CSF-expanded dendritic cells (DC)
that lacked immunosubunit expression ([47], and discussed
below). Thus, the biochemical analysis reveals that the
dramatic functional difference observed between the two
proteasome subtypes by immune assays is not the conse-
quence of the complete inability of standard proteasomes to
generate the epitope or epitope precursor peptide but rather
their relative inefﬁciency to do so. Combining this with
other similar observations, it appears that immunoprotea-
somes strongly inﬂuence the available amount and therefore
the quantity of a given epitope [48]. As a result, effects at
the immunological level will become detectable only once a
certain quantitative threshold of peptides is reached or
failed to be reached. This does not exclude the possible
existence of epitopes whose generation is indeed entirely
dependent on one of two proteasome subtypes.
Mass spectrometric analysis of peptide fragments pro-
duced in vitro from different virus or tumor antigen-derived
polypeptides harboring MHC class I epitopes indeed
indicated that the presence of immunosubunits affects the
cleavage site preference of the proteasome and in conse-
quence will change the relative amounts at which an epitope
or its precursor peptide is generated and hence will inﬂu-
ence the immuno-dominance of epitopes [17]. A direct
correlation of obtained mass signals with the amount of
peptides generated is considerably complicated by the
observation that, in many in vitro studies, substrate turnover
by 20S immunoproteasomes was found to be accelerated in
comparison to standard proteasomes [49]. Therefore, in
evaluating such studies and drawing conclusions for the
in vivo situation, one has to discriminate between peptide
fragments that are more abundant due to accelerated sub-
strate turnover and those that are more prevalent due to
altered proteasomal cleavage site usage. We recently solved
this problem by introducing so-called antitopes, i.e. peptide
fragments generated by cleavage within an epitope
sequence but containing the correct N-terminus of the
epitope or the epitope precursor, as internalreference for the
quantiﬁcation of relative amounts of epitopes that are
generated in vitro by either standard or immunoprotea-
somes [50]. Based on these analyses, it becomes evident
that immunoproteasomes, when compared with standard
proteasomes, exhibit an altered cleavage site preference
with a strong predominance to cleave behind residues that
represent the correct C-terminus of a MHC class I epitope.
Analysis of larger substrates also revealed that immuno-
proteasomes in many cases preferably generate epitope
precursor peptides with a more extended N-terminal
sequence that will facilitate TAP transport and require
trimming by aminopeptidases [51]. Nevertheless, correct
C-terminal cleavage site usage is not as robust as might be
concluded from the biochemical data. Presumably, as part
of an immune escape mechanism, mutations have naturally
evolved affecting residues that directly ﬂank the correct
C-terminal cleavage site, resulting in strongly reduced
epitope-generation efﬁciency. Thus, the recognition of the
Moloney murine leukemia virus (MuLV)-derived epitope
SSWDFTIV and the recognition of the p53-derived epitope
spanning residues 264–272 by speciﬁc CTLs was abolished
due to a singleamino acid substitution immediately ﬂanking
the C-terminal anchor residue of these epitopes [52]. An
example of such an immune escape mutation is a so-called
conservative Y/F residue exchange ﬂanking the immuno-
dominant hepatitis C virus (HCV) NS31073–1081 epitope that
was identiﬁed in a HCV strain isolated from chronically
infected patients [53]. The Y/F mutation impaired the
proteasome’s ability to generate the immunodominant
NS31073–1081 epitope in any signiﬁcant amount in vitro.
Furthermore, infection of human leukocyte antigen (HLA)-
A2 transgenic mice with a vaccinia virus expressing the
mutant NS3 protein demonstrated the inability of the pro-
teasome to generate this epitope. These studies, therefore,
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reactions perfectly resemble the in vivo situation [53]. In
addition, analysis of a CTL epitope encoded by AKV/MCF
type of MuLV differing from the sequence in Friend/
Moloney/Rauscher (FMR) type in one residue within the
epitope, as well as recent studies on a number of HIV
epitopes, revealed that amino acid exchanges within an
epitope sequence can also inﬂuence the proteasome’s abil-
ity for correct or efﬁcient C-terminal cleavage [54, 55].
Thus, although the preference of immunoproteasomes for
cleavage behind residues that serve as anchors for MHC
class I binding enhances antigen presentation, this immune
mechanism is counteracted by viral adaptation to alter
precisely these residues that allow efﬁcient proteasome-
mediated epitope liberation.
The role of PA28
IFN-c modulates the activity of the cellular antigen-pro-
cessing machinery not only through induction of
immunoproteasome formation but also through the induced
synthesis of the proteasome activator PA28 [56, 57]. PA28
binding to the 20S proteasome strongly stimulates the
hydrolysis of short ﬂuorogenic peptide substrates, and
detailed kinetic analysis showed that PA28 activates the
20S proteasome without affecting the active sites by either
facilitating substrate entry or product exit [33]. Detailed
biochemical studies, however, suggested that binding may
effect substrate channelling and the accessibility of active
sites for a given natural substrate, rather than affecting the
characteristics of the active sites themselves [34].
The most striking evidence for structural changes
imposed by PA28 on the 20S proteasomes was obtained
when the processing and presentation of two CTL epitopes
derived from a melanoma differentiation antigen, i.e.,
TRP2, was analyzed [58]. Detailed biochemical and
molecular experiments showed that the inability of mela-
noma18acellstopresenttheTRP2360–368epitopecorrelated
with a strongly impaired expression of PA28 in these cells,
which was also not restored by IFN- c treatment. Epitope
presentation and the ability to activate TRP2360–368 epitope-
speciﬁc CTLs by melanoma 18a cells were, however, fully
restored by transient transfection with cDNAs encoding the
PA28a and PA28b subunits [58, 59]. Interestingly, experi-
ments using the PA28-independent TRP2288–296 melanoma
epitope and the murine cytomegalovirus-derived pp89
epitope precursor peptide for epitope replacement revealed
that the ﬂanking sequences of PA28-dependent TRP2360–368
epitope can transfer PA28 dependence onto otherwise
PA28-independent epitopes. Moreover, the N-terminal
ﬂanking sequence turned out to be sufﬁcient to establish
PA28 dependence of an epitope by allowing PA28-induced
coordinated dual cleavages [60]. By which molecular
interactions the N-terminal ﬂanking sequence promotes
PA28 dependence remained unresolved in these studies, in
particular since the ﬂanking sequences of the human and
mouse TRP2 epitope do not reveal any obvious similarities.
However, the TRP2360–368 epitope generation is at
present the only well-studied example of an absolute PA28
dependence and therefore it may rather represent the
exception than the rule. Overexpression of PA28 in mouse
ﬁbroblasts was also shown to increase the sensitivity for
lysis by CTLs directed against a MCMV-pp89-derived
epitope [56]. In addition, TET-regulated expression of
PA28ab substantially increased the presentation of a
MuLV gagL-derived CTL epitope [61]. In total, the
investigation of several viral antigens shows that PA28
enhances the presentation of some viral epitopes without
increasing overall protein turnover or the turnover of viral
protein substrates, while the presentation of other virus-
derived epitopes was not affected [59]. Furthermore, this
enhanced peptide presentation was independent of the
presence of immunosubunits in the 20S proteasome [61]
and, perhaps somewhat surprisingly, so far no cooperative
effect between the two molecules has been observed [62].
Detailed in vitro analysis of the effects of PA28 on
proteasomal cleavage site usage revealed that PA28, similar
to immunoproteasomes, does not confer new cleavage
speciﬁcities. Instead, PA28 markedly enhances the fre-
quency of usage of speciﬁc preferred or minor cleavage
sites, resulting in an immediate liberation of the intervening
peptide fragments ([59], unpublished observation). Similar
to immunoproteasomes, PA28 also induces a drastically
accelerated turnover of synthetic polypeptide substrates that
harbor MHC class I epitopes. Somewhat in contrast to
immunoproteasomes, PA28 seems to affect the generation
and presentation of only a selective and minor fraction of
epitopes. Supporting this notion, it was shown that PA28
may also exert an allele-speciﬁc role by negatively inﬂu-
encing the processing of K
d (D
d) ligands and by supporting
the generation of K
b (L
d) epitopes [63]. Thus, PA28 seems
not to be a prerequisite for antigen presentation in general,
playing a role for the processing of only certain epitopes.
Considering that, independent of cytokine induction, PA28
is expressed in almost all tissues or cells analyzed, one is led
to infer that the observed involvement of PA28 in antigen
presentation may be only a secondary effect of a not yet
resolved true physiological function of PA28.
Expression patterns of proteasome immunosubunits
in vivo
As mentioned above, analyses of both cell lines and dif-
ferent mouse tissues have demonstrated that the
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expressed mainly in the lymphoid tissues such as thymus,
spleen and lymph nodes [64]. In lymphoid tissues, espe-
cially immature, DC express the immunosubunits at high
levels, which are only slightly upregulated following
maturation, or even downregulated, depending on the
maturation-inducing stimuli received [65–68]. Immuno-
subunit expression was further demonstrated for
macrophages [69], T cells [68] and B cells [70, 71], where
immunoproteasome abundance varied with the state of
differentiation [72]. Compared to lymphoid tissues, the
abundance of the immunosubunits in non-lymphoid
peripheral tissues is rather low [64, 73]. The residual levels
of immunosubunits, as detected by analysis of the tissues
ex vivo, in part may be explained by the presence of, for
example, DC and macrophages. However, most likely
immunosubunit expression in these tissues is not entirely
restricted to cells of hematopoietic origin. For example,
primary hepatocytes have been shown to express low
amounts of, mainly, LMP7, also in the absence of cytokine
stimulation [74, 75].
In vivo formation of immunoproteasomes
during infection
Because stimulation of cells that were maintained in tissue
culture with IFNc, as well as with IFNa, b or TNFa [74, 76,
77], upregulated immunosubunit expression, the question
arose whether (pro)inﬂammatory cytokines, released over
the course of pathogen-induced immune responses, altered
the composition of proteasomes in vivo. Indeed, both
infections with LCMV and with Listeria monocytogenes
were found to lead to an exchange of constitutive for
immunoproteasomes in livers of infected mice [48,
78]. Analysis of infected, IFNc, and IFN-a, receptor
gene-deﬁcient mice showed that, in the LCMV model,
approximately 50% of the replacement of constitutive by
immunoproteasomes was dependent on IFNc, whereas type
1 IFNs played a minor role [78]. In the case of Listeria-
infected mice, proteasomes of different tissues were
puriﬁed and tested for their ability to generate an immu-
noproteasome-dependent Listeria epitope. In tissues
lacking the IFNcR, but not the TNFR, the production of
this epitope was not upregulated following infection,
indicating an important role for IFNc in regulation of
epitope generation following infection with this bacterium
[48]. Also, infection of mice with Histoplasma capsulatum,
a fungus that induces strong Th1-biased immune responses,
led to replacement of constitutive for immunoproteasomes
in the infected tissues [75], which in this model was strictly
dependent on IFNc. In contrast, in chimpanzees infected
with HCV infection, increases in immunosubunit
expression in inﬂamed liver occur well before upregulation
of IFNc (and TNFa) expression, and coincide with type I
IFN responses [74]. Since exposure to type I IFN enhances
the expression of these proteasome components in a
hepatocyte cell line and primary hepatocytes in cell culture,
these data suggest that type I IFNs induce the upregulation
of immunoproteasome formation during acute HCV
infection. Taken together, these studies indicate that both
proinﬂammatory cytokines, which are already released by
innate immune cells in a very early stage of infection, as
well as IFNc which is released by NK cells, and T cells that
arrive approximately one to several days later at the site of
infection, contribute to the replacement of constitutive by
immunoproteasomes in inﬂamed tissues.
Effects of immunoproteasome expression
on pathogen-speciﬁc CD8 T cell responses
Pathogen-speciﬁc CD8 T cell responses are usually direc-
ted to only one immunodominant and a few subdominant
epitopes. The observation that DC express the IFNc-
inducible components permanently, whereas in peripheral
tissues the expression of these proteasome components as
well as that of other components of the MHC class I
antigen processing pathway is induced during infection,
both by proinﬂammatory cytokines and IFNc, strongly
suggests that immunoproteasomes serve to produce the
epitopes, detected by the pathogen-speciﬁc CD8 T cell
response. Thus, immediately after infection, pathogen-
derived antigens are processed by immunoproteasome-
containing DC and presented to naı ¨ve CD8 T cells, which
then are activated and start proliferating. Approximately
4 days later, fully functional, antigen-speciﬁc CD8 T cells
will migrate to the inﬂamed tissue, and there recognize the
epitopes, generated by the induced immunoproteasomes.
Indeed, different studies have demonstrated that immuno-
proteasome-mediated antigen processing shapes the ﬁne-
speciﬁcity of pathogen-speciﬁc CD8 T cell responses. For
example, quantifying CD8 T cell responses to seven viral
epitopes during inﬂuenza virus (PR8) infection in mice,
Chen et al. [79] found that the magnitude of the responses
to two dominant epitopes were dramatically decreased in
LMP2-gene-deﬁcient compared to wt mice, whereas the
frequencies of CD8 T cells responding to two subdominant
epitopes were increased. Further analyses of antigen
presentation kinetics by infected LMP2-deﬁcient compared
to wt cells in vitro, and of expansion of adoptively trans-
ferred wt CD8 T cells in PR8-infected LMP2-deﬁcient
mice, showed that quantitative differences in epitope
presentation explained the decreased response to one of the
dominant epitopes, derived from the viral acid polymerase
(PA), in LMP2-deﬁcient mice, as well as the enhanced
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experiments, however, also indicated that the poor CD8 T
cell responses to the second, dominant inﬂuenza epitope, in
the absence of LMP2, was not explained by aberrations in
viral epitope generation but probably by deﬁciencies in T
cell repertoire. Thus, in addition to processing of pathogen-
derived antigens, the immunosubunits may also inﬂuence
T cell selection, as will be discussed below. Further studies
by Pang et al. [80] showed that, like LMP2-deﬁcient mice,
LMP7 ? MECL-1-deﬁcient mice also failed to process
and present the inﬂuenza PA-derived epitope efﬁciently,
and mounted very weak CD8 T cell responses to this epi-
tope following infection with PR8. Importantly, insertion
of the PA epitope sequences in the neuraminidase stalk
restored proteasome-mediated generation of this eptitope
in immunosubunit-deﬁcient cells, and thereby rescued
the ability of the epitope to elicit dominant CD8 T cell
responses in immunosubunit-deﬁcient mice, infected with
the mutant inﬂuenza strain. Also, in the murine model of
LCMV infection, proteasome composition was found to
determine the ability of infected cells to process and
present different LCMV-derived epitopes [69]. Enhanced
presentation of one epitope, in the absence of LMP2 or
LMP7, correlated with higher frequencies of CD8 T cells
responding to this epitope in LCMV-infected LMP2 or
LMP7-gene-deﬁcient compared to wt mice. Thus, in this
example, immunoproteasomes limit efﬁcient generation of
one of the viral epitopes, and thereby the size of CD8 T cell
responses triggered by this epitope. A shift in immuno-
dominance hierarchy correlating with altered antigen
processing was also observed in immunosubunit-deﬁcient
HLA-A2/Kb transgenic mice that received a DNA prime,
recombinant vaccinia boost vaccination with the HBV env
and pol proteins [81]. In the absence of LMP7, numbers of
CD8 T cells reacting to two epitopes were decreased.
Responses to a third epitope were increased compared to
vaccinated control mice.
To determine how altered efﬁciencies of epitope liber-
ation inﬂuence the magnitude of CD8 T cell responses, a
recombinant L. monocytogenes strain (rLM-E1) secreting a
hybrid protein that encompassed the immunoproteasome-
dependent adenovirus E1B epitope was constructed [47].
Analysis of rLM-E1-infected BM-DC with peptide-speciﬁc
CTL revealed that deﬁciency of LMP7 and MECL-1
delayed (but did not abolish) the presentation of the E1B
epitope. Consistent with this defect in antigen processing,
LMP7 ? MECL-1-deﬁcient mice failed to mount E1B-
speciﬁc CD8 T cell responses following infection with
rLM-E1. In contrast, E1B was the dominant target of the
rLM-E1-speciﬁc CD8 T cell response in infected wt
controls. Alterations in TCR repertoire could not explain
the unresponsiveness of LMP7 ? MECL-1-deﬁcient mice,
as immunization with DC loaded with synthetic E1B
peptide primed E1B-speciﬁc CD8 T cells with high TCR
avidity. These T cells formed memory and expanded fol-
lowing secondary infection with rLM-E1, indicating that the
E1B epitope was presented in rLM-E1-infected immuno-
subunit-deﬁcient mice and triggered the re-activation of
CD8 T cell memory, but could not prime naı ¨ve CD8 T cells
during primary infection. Remarkably, LMP7 ? MECL-1-
deﬁcient mice also raised E1B-speciﬁc CD8 T cell responses
after receiving splenic APC of LMP7 ? MECL-1-deﬁcient
mice, infected 36 h earlier with rLM-E1. Thus, after 36 h,
the quantities of E1B on the APC were sufﬁcient to elicit a
CD8 T cell response. Taken together, these ﬁndings indicate
that the priming of CD8 T cells requires that their ligands
reach a speciﬁc threshold level on the priming pAPC,
already at an early time point following infection. We
conclude that immunoproteasomes, next to other contribut-
ing factors, can serve to lift the cell surface density of
speciﬁc epitopes over this threshold.
In conclusion, the changes in proteasome cleavage
preferences induced by immunosubunit incorporation
affect the efﬁciency of generation of multiple pathogen-
derived epitopes, and thereby the ﬁne speciﬁcity of path-
ogen-speciﬁc CD8 T cell responses. Nevertheless, there is
no compelling evidence that immunoproteasome-mediated
antigen processing plays a major role in pathogen resis-
tance. As reviewed above, the different immunosubunit-
deﬁcient mice analyzed so far mount pathogen-speciﬁc
CD8 T cell responses, although with different immuno-
dominance hierarchies, and acute infections with pathogens
such as LCMV are cleared with similar kinetics in LMP2-
and LMP7-deﬁcient mice as in wt mice [82]. On the other
hand, in a mouse model of CVB3 infection, Ja ¨kel et al. [83]
observed that early type I interferon responses and
concomitant upregulation of immunosubunit expression,
along with other components of the MHC class I antigen
processing pathway, correlated with resistance to chronic
infection. LMP7-deﬁcient mice show an enhanced
suscepitibility to Toxoplasma infection [84] and, remark-
ably, a delayed clearance of L. monocytogenes from the
liver that correlated with diminished production of an
immunoproteasome-dependent epitope [48]. Thus, analyses
of a large variety of infection models including different
types of pathogens may lead to a readjustment of our present
view, i.e. that immunoproteasomes play a limited role in
pathogen resistance.
A new pool of proteasome-generated antigenic peptides
Newly translated polypeptides, a large pool of which was
ubiquitylated, are thought to represent an important, yet not
the sole, source for MHC class I epitopes [5, 85]. It was
thus proposed, though not formally shown, that this pool is
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defective ribosomal products (DRiPs). The DRiP hypoth-
esis, although not undisputed, not only links antigen
processing to translation but would also guarantee that the
cellular immune system has access to its substrates before
they reach their ﬁnal destination within or outside the cell
[5, 85–87].
Until recently, there existed the canonical rule that
antigenic peptides of 8–10 residues in length, or precursor
peptides thereof which are generated by the 20S protea-
some, are peptide fragments with a linear sequence
identical to that found in the unprocessed parental protein.
This view, however, was dramatically changed by
reports in which antigenic peptides were identiﬁed which
were composed of two different peptide fragments whose
sequence was not contiguous in the parent protein. These
epitope peptides, identiﬁed by patient derived CTL were
post-proteolytic fusions of proteasomal cleavage products
and were shown to be generated by proteasome catalyzed
peptide splicing (PCPS) in a proposed transpeptidation
reaction (see also the review by Vigneron et al. [88]).
The ﬁrst spliced epitope peptide identiﬁed [89] repre-
senting tumor epitope was derived from FGF-5 (ﬁbroblast
growth factor) and was encoded as such by the FGF-5 gene
but it was a fusion of a ﬁve-residue peptide with a four-
residue peptide that was located 40 residues away.
Although the underlying mechanism was not elucidated at
the time, it appeared likely that the spliced peptide was
generated by the proteasome.
Consequently, two additional spliced immunogenic
peptides, derived from the melanocyte protein gp100 and
the SP100 nuclear phosphoprotein that were recognized
by CTLs, were identiﬁed [90]. Biochemical analysis
convincingly showed that splicing of the antigenic peptides
is catalyzed by the 20S proteasome in a reverse proteolysis
mechanism. In short, cleavage by the proteasome is the
result of a nucleophilic attack on the peptide bond by the
catalytic threonines that exist on the N-terminus of the b1,
b2 and b5 subunits or their IFN-c induced homologues,
b1i, b2i and b5i, in the immunoproteasome. The attack
results in the formation of an acylester intermediate.
Usually, these peptides are released from the proteasomes
by rapid hydrolyzation. Only when the acylester is stabi-
lized at the active site for a sufﬁcient time span can
N-termini of released peptide fragments compete with
water molecules and make a nucleophilic attack on the
ester bond of the acyl-enzyme intermediate, forming a new
peptide bond producing the spliced peptide. Furthermore, it
was also shown by Warren et al. [91] that two non-con-
tiguous peptides can also be fused by splicing in a reversed
order conﬁrming that the splicing reaction is dependent on
the retention time of the acyl-intermediate at the active site
threonine. The reversed splicing reaction also showed that,
after formation of the acyl-ester, the peptide is released into
the catalytic cavity of the proteasome where it can compete
with other peptides for the splicing reaction. This means
that, in theory, and neglecting the so far unknown sequence
requirements, any peptide fragment generated by prote-
asomal hydrolysis can participate in a splicing reaction
thereby giving rise to an unforeseen number of potential
splicing products and putative epitope containing peptides.
Since, under physiological conditions proteolysis is
normally favored over hydrolysis, the formation of new
immunologically relevant MHC class I ligands by PCPS
raised the possibility that reverse proteolysis may be
functionally more important than previously thought. On
the other hand, one has to acknowledge that only three
spliced epitope peptides have been reported in the literature
since their initial discovery in 2004 [89–92]. Thus, in
accord with the biochemical rules, PCPS is discussed to be
a relatively rare event and therefore supposed to be of very
limited immunological relevance. However, since not
every spliced peptide will fulﬁl the requirement of a MHC
class I ligand, the peptide splicing reaction as such may be
a considerably more frequent side reaction of proteasome
hydrolysis than previously assumed. But even if peptide
splicing is a relative rare event, PCPS may still play an
important role within the immune response. This is due to
the sensitivity of CD8? T cells, which are able to detect
very small numbers of MHC class I peptide complexes, and
in the most extreme example even a single MHC class I
complex.
However, so far, all presently available database search
algorithms fail to detect spliced peptide products. We
recently developed a theoretical/experimental method,
named SpliceMet, which combines the computer-based
algorithm ProteaJ with MS analyses of proteasome-gener-
ated peptides which in future will facilitate a systematic
and widely CTL-independent identiﬁcation of spliced
peptides.
Role of proteasome subunits in selection
of the TCR repertoire
T cells develop in the thymus and there are positively
selected for ability to recognize self-MHC, and then
negatively selected to eliminate T cells bearing TCR that
recognize autoantigens. While positive selection is based
on weak interactions of TCR with MHC molecules
presenting peptides of cellular proteins and stimulates
survival, negative selection is based on strong interactions
with peptide-loaded MHC molecules and induces apopto-
sis. Surprisingly, both Chen et al. [79] and Basler et al.
[93], analyzing CD8 T cell responses to inﬂuenza virus in
LMP2-deﬁcient and LCMV in MECL-1-deﬁcient mice
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cessed and presented efﬁciently failed to trigger T cell
responses in the absence of LMP2 or MECL-1. Indeed, wt
CD8 T cells transferred into LMP2- or MECL-1-deﬁcient
mice responded to these epitopes following infection with
inﬂuenza or LCMV. These ﬁndings led to the infererence
that the decreased responses in LMP2- and MECL-1-deﬁ-
cient mice were explained by alterations in the TCR
repertoire, and thus also strongly suggested an important
role for immunoproteasomes in peptide presentation in the
thymus and shaping of the TCR repertoire.
Further insight into the role of proteasome cleavage
preferences in CD8 T cell selection relies on recent data
by Murata et al. [73], who discovered a novel proteasome
subunit, b5t. The gene encoding b5t was identiﬁed in a
search for proteasome-related genes in a genome database,
and appeared to be located adjacent to the gene encoding
b5. b5t was found to be expressed only in cortical
thymical epithelial cells (cTEC), and to incorporate pref-
erentially into proteasome precursor complexes containing
LMP2 and MECL-1 [73]. A comparison of peptidase
activities of 20S and 26S containing b5o rb5t showed that
b5t incorporation selectively reduced the proteasomal
chymotrypsin-like activity. Thus, these ﬁndings suggest
that b5t incorporation alters the proteasomal cleavage site
usage in protein substrates, and thereby the repertoire of
peptides available for MHC class I binding in cells
expressing this subunit. In concordance with this conclu-
sion, b5t-deﬁcient mice showed a severe reduction in
numbers of single positive CD8 T cells in the thymus and
periphery, to approximately 20 and 30%, respectively, of
CD8 T cells in control mice, and failed to positively select
transgenic TCR recognizing the HY-antigen, an LCMV-
and an inﬂuenza-derived CD8 T cell epitope [73, 94]. The
severe impact of b5t on CD8 T cell repertoire was further
illustrated by the ﬁnding that mice lacking this subunit
showed a markedly enhanced susceptibility to inﬂuenza
virus infection [94], during which CD8 T cells are critical
for viral clearance [95]. On the other hand, ova-speciﬁc T
cells bearing the OT-1 tg TCR were selected in b5t-deﬁ-
cient mice [94], and these cells were responsive to
restimulation with ova peptide, ex vivo, indicating the
remaining CD8 T cells are functional. Taken together,
these data indicate that the cTEC-expressed b5t subunit
plays an important role in positive selection of CD8 T
cells in the thymus. b5t is found in 20S complexes mainly
in conjunction with LMP2 and MECL-1. This ﬁnding
nicely ﬁts with the observations reviewed above [79, 93]
that these subunits inﬂuence T cell selection, although to a
much lesser extent than b5t. Conversely, LMP7 and not b5t
is critically involved in selection of the OT-1 TCR, shown
previously by Osterloh et al. [96], using LMP7-deﬁcient
mice and conﬁrmed by the more recent observations in
b5t-deﬁcient mice, discussed above [94]. In support of a
role of LMP7 in positive selection, two-dimensional PAGE
of 20S complexes of cTECs, immunoprecipitated with
anti-b5t antibody, showed a faint spot for LMP7, indi-
cating that a fraction of the b5t-containing proteasomes
in cTEC are mixed complexes, also containing LMP7
[73] .T a k e nt o g e t h e r ,t h e s ed a t ai n d i c a t eap r e d o m i n a n t
role for the cTEC-expressed b5t subunit in the produc-
tion of MHC class I-presented peptides that mediate
positive selection and minor roles for LMP2, MECL-1
and LMP7.
Evidence for non-antigen processing-related roles
of immunoproteasomes in immune responses
The main function of proteasomes is the degradation of
intracellular proteins that are either defective or tagged,
usually by polyubquitin moieties. By selective protein
degradation, proteasomes regulate many cellular processes
including antigen processing, but also the activation of
transcription factors, cell proliferation and differentiation.
Thus, although most studies had focused on the role of
immunoproteasomes in antigen processing and CD8 T cell-
mediated immune responses, it remained plausible that the
immunosubunits could play a more pleiotrope role.
Moreover, mainly lymphoid cells express the immunosu-
bunits in an IFNc-independent fashion, suggesting that
these additional functions of immunoproteasomes may
impact on immune responses. First observations in support
of this possibility were by Chen et al. [79], who noticed
that the overall magnitude of the CD8 T cell response to
inﬂuenza virus in LMP2-deﬁcient mice was signiﬁcantly
lower than in wt mice. In addition, LMP2-deﬁcient CD8 T
cells transferred into wt mice failed to expand following
inﬂuenza infection, as was also later found for T cells
lacking MECL-1 [93] or MECL-1 and LMP7 [79, 80].
Thus, the immunosubunits may be involved in lymphocyte
survival or expansion. Recently, Hensley et al. [70]
reported that LMP2-deﬁcient but not LMP2 ? MECL-1-
or LMP7 ? MECL-1-deﬁcient mice displayed severely
reduced numbers of mature B cells, CD4 and CD8 T cells
in the spleen. Further analyses of the LMP2-deﬁcient
mouse strain revealed severe defects in B cell and DC
function, resulting in reduced primary anti-viral antibody
responses with reduced isotype switch, and a reduced
production of different pro-inﬂammatory cytokines by
inﬂuenza virus-infected LMP2-deﬁcient BM DC in cell
culture. LPS-stimulated LMP2-deﬁcient B cells showed
reduced ijB degradation, suggesting that deﬁcient NFjB
activation may explain some of the defects observed in
LMP2-deﬁcient mice. Because mice lacking both LMP2
and MECL-1 did not show any major aberrations in
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LMP2 were attributed to the formation of mixed protea-
somes, containing b1 in combination with MECL-1 and
LMP7, a proteasome type that is disfavored when LMP2 is
present.
Different studies in mice lacking MECL-1 or both
LMP7 and MECL-1 further supported a role for immuno-
sububunits in T cell proliferation. Caudill et al. [97]
reported that the absence of MECL-1 or of both LMP7 and
MECL-1 led to enhanced CD4/CD8 ratios in the peripheral
lymphoid tissues. A further analysis of CD4/CD8 T cell
ratios in BM chimeric mice showed that the ratios of
LMP7 ? MECL-1-deﬁcient CD4/CD8 T cells were also
enhanced when these T cells developed in wt mice [98].
Strikingly, in mixed chimeric mice, consisting of an
LMP7 ? MECL-1-deﬁcient recipient reconstituted with a
mix of LMP7 ? MECL-1-deﬁcient and wt BM, the
immunosubunit-deﬁcient and wt T cell populations main-
tained their characteristically different CD4/CD8 ratios,
despite the fact that these T cells developed in the same
thymic environment and circulated in the same peripheral
lymphoid tissues [98]. Thus, as environmental factors
cannot explain the aberrant relative expansion of the CD4
and CD8 T cell subsets in mice lacking MECL-1, it must
be concluded that T cell-expressed MECL-1 regulates
homeostatic T cell expansion or survival, perhaps by
altered degradation of anti- or pro-apoptotic proteins or
altered transcription factor activation.
A recent study [99] demonstrated that treatment with an
LMP7-selective inhibitor, PR-957, reduced the production
of TNFa, IL-23 and IL-6 by LPS-stimulated human
PBMC and of IFNc and IL-2 by activated human T cells.
Also, activated wt but not LMP7-deﬁcient mouse spleno-
cytes produced reduced amounts of cytokines following
PR-957 treatment, conﬁrming that the observed effects
were a result of LMP7-inhibition. Remarkably, no differ-
ences in cytokine production were observed between
untreated wt and LMP7-deﬁcient mouse splenocytes,
demonstrating that the constitutive subunits/b5 can com-
pensate for the role of LMP7 in cytokine production. To
determine whether selective inhibition of LMP7 impacts
on ongoing inﬂammatory responses in vivo, mice with
collagen- or collagen antibody-induced arthritis were
treated with PR-957. In both models, experimental arthritis
was ameliorated following injection of PR-957, probably
due to reduced production of inﬂammatory cytokines and
reduced cellular inﬁltration. Taken together, these data as
well as the ﬁndings by Hensley at al. in LMP2-deﬁcient
mice ([70]; see above) indicate that proteasomes play an
important role in regulation of cytokine production, and
thereby reveal yet another important function of (immuno)
proteasomes.
Defective ribosomal products, immunoproteasomes
and peptide quantity
Poly-ubiquitylated nascent defective proteins (DRiPs) are
thought to represent the major but not the sole source for
MHC class I peptide ligands [5, 85] (for details, see the
review by Dolan et al. [100]). The DRiP hypothesis, which
links antigen processing to translation, would guarantee
that the cellular immune system has immediate access to its
substrates, and thus uncouples antigen presentation from
intracellular protein destination or half-life [5, 85–87].
However, the idea that a large amount of newly translated
proteins should be misfolded or harbor translational errors
also raised some doubts with regard to the validity of the
hypothesis [101, 102]. Thus, considering that all major
components of the antigen processing pathway are upreg-
ulated upon IFN stimulation and that the deﬁnition of
‘‘defect’’ remained unclear, there also existed no explana-
tion of how DRiP levels can be adapted to changing
immunological requirements in terms of peptide supply.
Recently, a somewhat surprising solution to this prob-
lem has been offered by Seifert and colleagues [103]. Their
study revealed that IFNs trigger a strong and transient
accumulation of oxidant-damaged nascent poly-ubiquity-
lated proteins and that, under proinﬂammatory conditions,
DRiPs from a pool of oxidized, unfolded nascent proteins
marked by poly-ubiquitin chains underwent rapid degra-
dation by the 26S proteasome. The increase in the DRiPs
pool is brought about by the IFN-induced formation of
ROS, mTOR-dependent enhanced translation and strongly
increased poly-ubiquitylation activity. Interestingly, during
the early phase of IFN stimulation, the generation of these
DRiPs signiﬁcantly exceeds the degradation capacity of the
UPS leading to a strong, transient accumulation of poly-
ubiquitylated proteins and formation of aggresome-like-
induced structures (ALIS). The elimination and efﬁcient
turnover of these accumulated defective and ubiquitylated
proteins essentially requires the presence of 26S immuno-
proteasomes, exhibiting an approximately three- to
fourfold higher degradation capacity than standard 26S
proteasomes. Supporting their importance in overcoming
IFN-induced oxidative stress, the absence of immunopro-
teasomes, as in LMP7-deﬁcient mice, resulted in the
inability of cells to eliminate the accumulating DRiPs, in
enhanced ALIS formation and increased susceptibility to
apoptosis. These experiments show that physiologically a
primary function of immunopoteasomes resides in the
maintenance of protein homeostasis under proinﬂammatory
conditions and that, in consequence, as a result of its
enhanced degradation capacity, immuno-26S proteasomes
also strongly expand the pool of peptides available for
MHC class I antigen presentation.
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123In conclusion, the proteasome system plays a funda-
mental role in immune regulation through a variety of
mechanisms including MHC class I antigen processing,
lymphocyte survival and regulation of cytokine production/
inﬂammation. Consequently, inhibition of speciﬁc prote-
asomal active sites may impact on all these proteasome-
mediated processes, which should be carefully considered
when analyzing the role of speciﬁc proteasome compo-
nents in speciﬁc immune effector functions.
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